Ceritinib (Spexib) 150mg*150's | Novartis India Originator | GLT

Generic Information: Spexib (India)

Spexib is Novartis's own Indian-market brand of ceritinib — the same originator medicine sold internationally as Zykadia, and labelled for sale in India only. Each hard capsule delivers 150 mg of ceritinib, and this multipack holds 150 capsules (three packs of 50). Ceritinib is a targeted oral therapy for ALK-positive non-small cell lung cancer, designed for patients whose disease has progressed on first-line crizotinib.

What Is Ceritinib (Spexib) Used For?

Ceritinib is indicated for metastatic non-small cell lung cancer (NSCLC) that carries an ALK gene rearrangement. It is used both in patients who have become resistant to crizotinib and, in some regions, as an initial treatment for newly diagnosed ALK-positive disease. For people with this specific molecular subtype of lung cancer, ceritinib offers a potent, oral alternative when first-generation ALK therapy stops working.

How Does Ceritinib Work?

Ceritinib blocks anaplastic lymphoma kinase (ALK), a protein that drives tumour growth in a subset of lung cancers. By inhibiting ALK — and, to a lesser extent, related kinases such as IGF-1R and ROS1 — the drug shuts down the growth signals that cancer cells depend on. Because it is a second-generation inhibitor, it remains active against many of the ALK mutations that make tumours resistant to crizotinib, which is why it is so valuable after disease progression.

Indications

The approved indication is ALK-positive metastatic NSCLC confirmed by an FDA- or locally-approved ALK test. Ceritinib is a disease-control therapy rather than a cure; it is prescribed to slow progression, shrink tumours where possible, and extend survival in patients whose lung cancer has spread.

Dosage

The recommended dose is 450 mg (three 150 mg capsules) taken once daily with food, which improves tolerability without reducing effectiveness. The earlier 750 mg once-daily fasting schedule is also described in the label. A 150-capsule multipack therefore covers 50 days at the 450 mg daily dose. Dose interruptions or reductions are managed by the treating oncologist based on side effects and liver-function tests.

Side Effects

The most common side effects are gastrointestinal — diarrhoea, nausea, vomiting and abdominal pain — together with fatigue and reduced appetite. Important but less common effects include liver enzyme elevation, high blood sugar, prolongation of the QT interval on the ECG, and inflammation of the lungs (pneumonitis). Liver function and blood glucose are monitored regularly during treatment, and patients are advised to report persistent diarrhoea, yellowing of the skin, or new breathing difficulty promptly.

Storage

Store Spexib capsules at room temperature in the original container, protected from moisture and light, and out of the reach of children. Do not use past the expiry date shown on the pack.

Why Choose Spexib Through GLT?

For overseas patients and institutions, sourcing ceritinib through GLT provides access to a genuine Indian-market product at a price well below Western retail list prices. A 150-capsule monthly pack also simplifies supply — one box covers a full month of treatment, reducing reorder frequency and shipping cost compared with smaller packs.

How to Order

To order Spexib (ceritinib) from GLT, contact us on WhatsApp at +86 15234153837 or by email at [email protected]. We will confirm current availability, pricing and delivery to your country, and we ship from a Hong Kong-licensed facility.

FAQ

Is Spexib the same as Zykadia? Yes — Spexib is Novartis's own Indian-market brand of the same originator ceritinib sold as Zykadia in the United States, Europe and China. Same molecule, same manufacturer, different market name.

How long does a 150-capsule pack last? At the standard 450 mg once-daily dose (three capsules), one pack lasts about 50 days; at 750 mg daily (five capsules), it lasts 30 days.

Do I need a prescription? Yes, ceritinib is a prescription-only oncology medicine, and a valid prescription from a licensed oncologist is required.